Protara Therapeutics, Inc.

TARA

Protara Therapeutics, Inc.

TARA

Insider Sentiment (TTM):

Last Purchase:2025-05-14Last Sale:2026-04-08Shares Purchased (TTM):0Shares Sold (TTM):23,732

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:45,494,950Shares Outstanding:57,538,833Institutional Ownership Pct.:79.07%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	17	15	50	13	31	91	163	52	90	52	40	34
Marketable Securities Current	125	121	106	120	91	33	7	30	-	3	26	40
Prepaid Expense And Other Assets Current	4	4	4	3	3	2	2	4	3	3	3	4
Assets Current	146	140	160	136	125	127	172	85	92	58	69	78
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Marketable Securities Noncurrent	19	42	42	1	23	33	-	-	-	-	-	-
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	3	3	3	3	4	4	4	5	5	5	5	6
Other Assets Noncurrent	-	-	-	-	-	-	-	-	-	-	-	3
Other Assets	6	6	3	3	3	3	3	3	3	3	3	-
Assets	176	192	209	145	157	169	181	94	102	68	79	88
Liabilities Current
Accounts Payable Current	5	4	3	5	5	2	4	2	1	1	2	3
Liabilities And Stockhold…
Accrued Liabilities Current	7	4	6	4	3	4	5	5	3	4	3	3
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Liabilities Current	13	9	11	10	10	7	11	9	6	6	6	7
Operating Lease Liability Noncurrent	1	2	2	2	3	3	3	4	4	4	4	5
Liabilities	15	11	13	12	13	10	14	12	10	10	11	12
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	503	502	499	417	416	415	412	314	313	270	269	267
Retained Earnings Accumulated Deficit	-342	-320	-302	-285	-272	-257	-245	-232	-221	-211	-200	-190
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	0	-	-0	-0	-0
Stockholders Equity	161	181	196	132	144	158	167	82	92	58	68	77
Liabilities And Stockholders Equity	176	192	209	145	157	169	181	94	102	68	79	88
Series One Convertible Preferred Stock	-	0	0	0	0	0	0	0	0	0	0	-0
Series1 Preferred Stock	-	-	-	-	-	-	-	-	-	-	0	0
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100	100
Common Stock Shares Issued	59	55	54	39	39	39	35	21	21	11	11	11
Shares Outstanding	59	55	54	39	39	39	35	21	11	11	11	11

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-20.00%	-21.92%	-22.50%	-	-	-	-	-	-	-	-	-
2025	-9.79%	-14.54%	-1.19%	1.61%	60.00%	67.10%	23.18%	18.76%	56.29%	-10.51%	-6.83%	-18.56%
2024	-3.11%	-21.80%	-22.84%	-3.38%	-8.70%	9.18%	129.07%	137.98%	90.70%	26.17%	19.01%	-13.77%
2023	-	-	-	-	-	-	-11.85%	35.56%	41.48%	-0.55%	-20.27%	-23.01%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	10.97	15.69	14.58	13.69	12.82	18.03	15.71	9.85	16.33	10.53	11.17	11.49
Quick Ratio	10.70	15.22	14.22	13.39	12.52	17.72	15.54	9.43	15.86	10.04	10.67	10.93
Working Capital	132.83M	131.08M	148.57M	125.74M	115.33M	119.51M	161.19M	76.44M	86.57M	52.41M	62.56M	71.04M
Leverage & Debt
Debt to Equity	0.09	0.06	0.07	0.09	0.09	0.06	0.09	0.15	0.10	0.17	0.16	0.15
Debt Ratio	0.08	0.06	0.06	0.09	0.08	0.06	0.08	0.13	0.09	0.14	0.13	0.13
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.15	-1.10	-1.34	-1.25	-1.20	-1.12	-2.17	-1.88	-1.92	-3.72	-3.57	-6.10
Free Cash Flow Per Share TTM	-1.09	-1.10	-1.32	-1.15	-1.06	-0.99	-1.74	-1.58	-1.57	-3.07	-3.32	-2.99
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	37.66%	39.40%	28.80%	25.81%	25.00%	6.93%	10.33%	-39.21%	-39.27%	-33.89%	-38.71%	85.87%
EPS Growth (1Y)	-4.62%	-1.38%	-38.08%	-33.54%	-37.21%	-70.00%	-39.29%	-69.11%	-67.66%	-34.57%	-39.10%	84.52%
Valuation Metrics
P/E TTM	-3.33	-4.74	-3.97	-3.48	-2.52	-3.82	-2.44	-0.97	-1.09	-1.08	-0.53	-0.27
P/B TTM	1.44	1.65	1.16	1.39	0.89	1.09	0.65	0.50	0.48	0.78	0.31	0.25
Market Cap	233.05M	299.78M	228.32M	183.88M	128.08M	173.42M	108.73M	40.86M	44.16M	45.80M	21.25M	18.95M
Enterprise Value	215.22M	284.30M	177.91M	170.59M	95.84M	81.21M	140.99M	-11.64M	-46.16M	-7.18M	-19.08M	-15.56M
Calculated Values
Free Cash Flow TTM	-66.49M	-63.05M	-56.46M	-48.79M	-44.78M	-40.25M	-35.87M	-35.26M	-33.42M	-35.09M	-37.60M	-33.93M
Net Debt	-17.82M	-15.48M	-50.40M	-13.30M	-32.24M	-92.21M	32.26M	-52.50M	-90.33M	-52.98M	-40.33M	-34.51M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-08Sale

Owner: Zummo, Jacqueline

Title: Chief R&D Officer

Shares: 1,134

Price/Share: $5.40

Value: $6,123.60

Shares Owned: 94,827

Relationship: Officer

Ownership: Direct

2026-04-01Sale

Owner: Zummo, Jacqueline

Title: Chief R&D Officer

Shares: 22,598

Price/Share: $5.26

Value: $118,865.48

Shares Owned: 95,961

Relationship: Officer

Ownership: Direct

2025-05-14Purchase

Owner: Levy, Richard S

Title: -

Shares: 20,000

Price/Share: $3.19

Value: $63,800.00

Shares Owned: 51,000

Relationship: Director

Ownership: Direct

2025-03-26Sale

Owner: Zummo, Jacqueline

Title: Chf Scientific Operations Off

Shares: 21,224

Price/Share: $4.53

Value: $96,144.72

Shares Owned: 98,861

Relationship: Officer

Ownership: Direct

2024-09-12Sale

Owner: Opaleye, Management Inc.

Title: -

Shares: 126,301

Price/Share: $1.71

Value: $215,974.71

Shares Owned: 45,000

Relationship: TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-08	Zummo, Jacqueline	Officer	Chief R&D Officer	Direct	Sale	1,134	5.40	$6,123.60	94,827	4
2026-04-01	Zummo, Jacqueline	Officer	Chief R&D Officer	Direct	Sale	22,598	5.26	$118,865.48	95,961	4
2025-05-14	Levy, Richard S	Director	-	Direct	Purchase	20,000	3.19	$63,800.00	51,000	4/A
2025-03-26	Zummo, Jacqueline	Officer	Chf Scientific Operations Off	Direct	Sale	21,224	4.53	$96,144.72	98,861	4
2024-09-12	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	126,301	1.71	$215,974.71	45,000	4
2024-09-10	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	25,500	1.77	$45,135.00	53,100	4
2024-07-16	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	11,396	2.44	$27,806.24	56,500	4
2024-07-11	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	47,993	2.40	$115,183.20	60,000	4
2024-07-01	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	8,288	2.12	$17,570.56	87,500	4
2024-06-28	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	17,994	2.07	$37,247.58	85,000	4
2024-06-25	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	12,725	2.26	$28,758.50	102,471	4
2024-05-31	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	5,824	2.90	$16,889.60	108,696	4
2024-05-22	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	9,800	3.01	$29,498.00	123,750	4
2024-05-17	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	70,885	3.20	$226,832.00	126,050	4
2024-05-10	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Sale	151,700	3.11	$471,787.00	2,380,294	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

79.07%

Inst. Shares: 45,494,950

Shares Outstanding: 57,538,833

2025-12-31

92.54%

Inst. Shares: 39,638,454

Shares Outstanding: 42,836,129

2025-09-30

61.65%

Inst. Shares: 26,061,731

Shares Outstanding: 42,272,104

2025-06-30

69.82%

Inst. Shares: 29,513,764

Shares Outstanding: 42,270,855

2025-03-31

70.26%

Inst. Shares: 28,601,911

Shares Outstanding: 40,707,937

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	45,494,950	57,538,833	79.07%
2025-12-31	39,638,454	42,836,129	92.54%
2025-09-30	26,061,731	42,272,104	61.65%
2025-06-30	29,513,764	42,270,855	69.82%
2025-03-31	28,601,911	40,707,937	70.26%
2024-12-31	29,502,876	20,592,847	143.27%
2024-09-30	10,399,898	22,329,772	46.57%
2024-06-30	10,393,444	21,233,163	48.95%
2024-03-31	4,462,005	11,420,948	39.07%
2023-12-31	4,238,425	11,331,338	37.40%
2023-09-30	5,051,595	11,347,887	44.52%
2023-06-30	4,957,425	11,307,842	43.84%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Protara Therapeutics, Inc. (TARA) — SEC Financial Statements & Analysis

Protara Therapeutics, Inc. (TARA) is a biological products, (no diagnostic substances) company. Protara Therapeutics, Inc. trades on Nasdaq as: TARA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Protara Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.09x, a Price-to-Book (P/B) ratio of 1.44x (TTM), at a market cap of $233.05M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.09x
P/B TTM: 1.44x
Market Cap: $233.05M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Protara Therapeutics, Inc. in?

Protara Therapeutics, Inc. (TARA) operates in the Biological Products, (No Diagnostic Substances) industry.

What is TARA's market cap?

Protara Therapeutics, Inc. (TARA) has a market capitalization of $233.05M as of 2026-06-30.

What exchange does TARA trade on?

Protara Therapeutics, Inc. (TARA) trades on the Nasdaq.